Fox Run Management L.L.C. Takes $203,000 Position in Immunome, Inc. $IMNM

Key Points

• Fox Run Management L.L.C. has acquired a new stake in Immunome, Inc., purchasing 30,220 shares valued at approximately $203,000 in the first quarter.
• Immunome's stock saw a decline of 4.5%, currently trading at $9.57, with a 52-week range between $5.15 and $16.73.
• Several hedge funds, including Invesco Ltd. and MetLife Investment Management LLC, have recently increased their holdings in Immunome, demonstrating strong institutional interest with 44.58% of the stock owned by these investors.

Fox Run Management L.L.C. bought a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 30,220 shares of the company's stock, valued at approximately $203,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in Immunome by 2,822.9% during the first quarter. GAMMA Investing LLC now owns 6,138 shares of the company's stock worth $410,000 after purchasing an additional 5,928 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Immunome during the fourth quarter worth $70,000. Tower Research Capital LLC TRC lifted its stake in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in Immunome during the fourth quarter worth $95,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Immunome during the first quarter worth $95,000. 44.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IMNM has been the subject of several recent analyst reports. JPMorgan Chase & Co. cut their target price on Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Wall Street Zen upgraded Immunome from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Evercore ISI started coverage on Immunome in a research note on Friday. They issued an "outperform" rating and a $18.00 price target for the company. Guggenheim reiterated a "buy" rating and issued a $25.00 price target on shares of Immunome in a research note on Monday. Finally, Wedbush reiterated an "outperform" rating and issued a $21.00 price target on shares of Immunome in a research note on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $22.50.

Immunome Trading Up 2.4%

NASDAQ:IMNM traded up $0.24 during trading hours on Tuesday, hitting $10.16. 1,154,934 shares of the company were exchanged, compared to its average volume of 630,569. The stock has a market capitalization of $884.33 million, a price-to-earnings ratio of -3.30 and a beta of 1.93. Immunome, Inc. has a one year low of $5.15 and a one year high of $16.73. The company has a fifty day simple moving average of $9.72 and a 200 day simple moving average of $8.87.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.02. The business had revenue of $4.02 million during the quarter, compared to analyst estimates of $1.03 million. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. Equities research analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Activity

In other Immunome news, Director Jean Jacques Bienaime acquired 5,000 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were bought at an average cost of $9.38 per share, with a total value of $46,900.00. Following the purchase, the director directly owned 36,415 shares of the company's stock, valued at $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.69% of the stock is owned by corporate insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.